Ann: Change of Company Name-MNQ.AX, page-12

I have said in the past that people should not approach it as a EPT vs RAP battle , both companies are not competitors they co exist in a emerging industry of medical phone apps.

I hope both do extemely well and certainly I think the market cap of plus $300M for RAP which is yet to have a commercial product until at least next year bodes as a potential beacon to the market about how successful EPT can be.

The success of each is great for all holders

But in comparison I do believe that commercial product timelines stated by both companies is next year which is about the same , EPT will have the development of the kids app to roll out later on as well which I think will be huge add on

Then a key criteria for me is management , as I said before nothing against the RAP management but when you compare CVs , EPT clearly have the guys who have done this biotech commercialisation before for Cochlear and Resmed, so I weight more confidence in EPT management to get it done, but I hope both managements can deliver